Receive our newsletter – data, insights and analysis delivered to you
June 4, 2009

Novel Novavax Vaccine to be Evaluated for Flu Virus

Novavax and the US Division of Microbiology and Infectious Diseases (DMID) have announced plans to cooperate on the evaluation of a virus-like particle (VLP) as a vaccine candidate against the influenza A (H1N1) virus. The company produced the first batch of H1N1 VLPs in its laboratories

By cms admin

Novavax and the US Division of Microbiology and Infectious Diseases (DMID) have announced plans to cooperate on the evaluation of a virus-like particle (VLP) as a vaccine candidate against the influenza A (H1N1) virus.

The company produced the first batch of H1N1 VLPs in its laboratories in May, only three weeks after the US Centers for Disease Control and Prevention (CDC) announced the genetic sequence of the novel H1N1 virus, which was isolated from an infected person located in California.

Novavax’ VLPs contain hemagglutinin (HA), neuraminidase (NA) and matrix 1 (M1) proteins, which were found in this strain.

The size and structure of the VLPs are nearly identical to those of the novel H1N1 virus, but are not infectious as they lack the genes necessary for replication.

Novavax president and CEO Rahul Singhvi said that the company’s proprietary recombinant cell culture technology had enabled production of custom VLPs against this strain of influenza within weeks.

“The company has committed necessary resources to respond as rapidly as possible to construct and manufacture a VLP vaccine against this new H1N1 influenza virus,” said Singhvi.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Purified influenza A VLPs are being sent to scientists at the CDC and DMID for studies in animal models. The company has also completed genetic engineering and manufacture of the master seed stock necessary to produce larger quantities of the investigational H1N1 VLP vaccine under cGMP conditions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU